Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cisplatin
Drug ID BADD_D00474
Description Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
Indications and Usage For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
Marketing Status approved
ATC Code L01XA01
DrugBank ID DB00515
KEGG ID D00275
MeSH ID D002945
PubChem ID 5702198
TTD Drug ID D0U5HU
NDC Product Code 16729-288; 25021-253; 0143-9505; 68554-0077; 0143-9504; 68001-283; 44567-509; 50711-0001; 44567-510; 63323-103; 0703-5747; 0703-5748; 44567-530; 60505-6277; 68083-163; 44567-511; 49452-2078; 54875-0001; 67184-0010; 68083-162; 70860-206; 49812-0009; 72659-864
UNII Q20Q21Q62J
Synonyms Cisplatin | cis-Diamminedichloroplatinum(II) | Platinum Diamminodichloride | Diamminodichloride, Platinum | cis-Platinum | cis Platinum | Dichlorodiammineplatinum | cis-Diamminedichloroplatinum | cis Diamminedichloroplatinum | cis-Dichlorodiammineplatinum(II) | NSC-119875 | Platino | Platinol | Biocisplatinum | Platidiam
Chemical Information
Molecular Formula PtCl2(NH3)2
CAS Registry Number 15663-27-1
SMILES N.N.Cl[Pt]Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Disease complication08.01.03.0870.000112%Not Available
Gallbladder rupture12.01.17.005; 09.03.02.0120.000168%Not Available
Inadequate analgesia12.02.20.006; 08.06.01.0400.000112%Not Available
Laryngeal cancer stage IV22.08.02.010; 16.19.03.0030.000168%Not Available
Lung adenocarcinoma stage III22.08.01.025; 16.19.01.0120.000112%Not Available
Mucosal disorder08.01.06.0290.000112%Not Available
Myelosuppression01.03.03.0150.000895%Not Available
Oesophagobronchial fistula22.03.02.015; 07.11.05.0220.000112%Not Available
Pharyngeal necrosis24.04.09.014; 22.04.05.0270.000112%
Presbyacusis04.02.01.0100.000112%Not Available
Reduced facial expression19.01.02.021; 17.01.05.0160.000112%Not Available
Renal tubular dysfunction20.05.03.0280.000224%Not Available
Renal tubular injury20.01.07.0200.000224%Not Available
Superficial vein thrombosis24.01.02.0160.000302%Not Available
Therapeutic product effect incomplete08.06.01.0520.001791%Not Available
Thrombophlebitis migrans16.32.01.016; 24.01.01.0430.000112%Not Available
Vesical fistula20.03.01.0270.000168%Not Available
The 20th Page    First    Pre   20    Total 20 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene